Optimising advanced RCC treatment: the place of Fotivda®?(tivozanib) in 2019 and beyond

Optimising advanced RCC treatment: the place of Fotivda®?(tivozanib) in 2019 and beyond

kidneycancer

1 year
216 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Manuela Schmidinger, MD, Camillo Porta, MD, Romano Danesi, MD, PhD, Brian I. Rini, MD discuss Optimising advanced RCC treatment: the place of Fotivda®?(tivozanib) in 2019 and beyond at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia
Up Next Autoplay